Access to modern HER2-targeted therapy and early diagnosis are required to improve outcomes of patients with HER2-positive breast cancer worldwide. We conducted this study to determine the factors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback